Drug Trial Radar · NCT07275840
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Aug 30, 2026
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)Industry
- Sponsor type
- Industry
- First posted
- Dec 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
IBI302 8mg doseDrug
8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants whose best corrected visual acuity (BCVA) of the study eye decreased by less than 15 letters from baseline as measured by the visual acuity chart in the early treatment diabetic retinopathy study (ETDRS) at week 52Time frame: Week52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai general hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.